Table 3 Estimated annual GP, specialist and liver ultrasound appointments required in year 4 of the program and sensitivity analysis of incremental service utilisation, compared to baseline (no program)
| Treatment group | Number of people* | Annual appointments related to CHB surveillance and/or treatment | ||
|---|---|---|---|---|
|
GP appointments (averaged per GP) |
Specialist (averaged per specialist) | Ultrasound | ||
| Routine Surveillance (GP-led) | 745 | 1,303 | ||
| Enhanced Surveillance (GP-led) | 263 | 460 | 263 | |
| Interferon (Specialist-led) | 8 | 44 | 7 | |
| Entecavir (Specialist-led) | 201 | 781 | 195 | |
| Other** | 236 | 18 | 8 | |
| Total cohort | 1,452 | 1,763 | 843 | 473 |
| Baseline (no program) | 1,452 | 28 | 84 | 54 |
| Incremental service utilisation (over no program) | ||||
| At 25% program uptake | 0 |
1,734
(5.0) |
759
(25.3) | 419 |
| At 10% program uptake | 0 |
694
(2.0) |
304
(10.1) | 167 |
| At 65% program uptake | 2 |
4,509
(12.9) |
1,974
(65.8) | 1,089 |
| With viral load cut-off of 2000 IU/ml at all ages in program | 0 |
1,648
(4.7) |
961
(32.0) | 557 |
| If ALT cut-off varies, so 20% have high ALT | 0 |
1,908
(5.5) |
274
(9.1) | 380 |
| If ALT cut-off varies, so 90% have high ALT | 0 |
1,475
(4.2) |
1,370
(45.7) | 427 |
| If age at enrolment is ≥ 40 years (instead of 35) | 0 |
1,327
(3.8) |
616
(20.5) | 344 |